Linked Life Data

2492225

Source:http://linkedlifedata.com/resource/pubmed/id/2492225

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1989-3-1
pubmed:abstractText
Acetazolamide (Diamox) (AZM) was evaluated as an adjunct to carbamazepine (CBZ) monotherapy in 48 refractory partial seizure patients at a tertiary care referral center. Patient ages ranged from 6 to 64 years (average 28 years). Seizure frequencies for the pre-AZM baseline period (CBZ monotherapy) were compared with the seizure frequencies at different daily doses of AZM. Patients with a 50% decrease in seizure frequency were considered responders. Twenty-one patients were responders (44%) and three became completely seizure-free. Effective doses ranged from 3.8 to 22.0 mg/kg/day. Effective plasma concentrations ranged from 1 to 22 micrograms/ml in selected patients. Durations of response time to AZM ranged from 3 to 30 months (average 12.9 months). Three patients lost response, one temporarily. Side effects were seen in 10 patients, requiring discontinuation in three.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0013-9580
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
74-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures.
pubmed:affiliation
Department of Neurology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27103.
pubmed:publicationType
Journal Article